PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
35033885-0	2022	Discovery of a benzimidazole-based dual FLT3/TrKA inhibitor targeting acute myeloid leukemia.	benzimidazole	15-28	fms related receptor tyrosine kinase 3	Homo sapiens	40-44	
35148084-0	2022	Identification of the Benzoimidazole Compound as a Selective FLT3 Inhibitor by Cell-Based High-Throughput Screening of a Diversity Library.	benzimidazole	22-36	fms related receptor tyrosine kinase 3	Homo sapiens	61-65	
35148084-7	2022	Our findings establish the specific activity of the benzoimidazole compound against FLT3/ITD leukemia and warrant further investigation in this subset of leukemia patients with poor prognosis.	benzimidazole	52-66	fms related receptor tyrosine kinase 3	Homo sapiens	84-88	
35033885-4	2022	Guided by ligand-based design and structure simplification of the FLT3 inhibitor, quizartinib, we developed a benzimidazole-based small molecule, 4ACP, that exhibited nanomolar activity against wild-type FLT3, FLT3-Internal tandem duplications (FLT3-ITD), and FLT3-D835Y (FLT3-TKD) mutation (IC50 = 43.8, 97.2, and 92.5 nM respectively).	benzimidazole	110-123	fms related receptor tyrosine kinase 3	Homo sapiens	66-70	
35033885-4	2022	Guided by ligand-based design and structure simplification of the FLT3 inhibitor, quizartinib, we developed a benzimidazole-based small molecule, 4ACP, that exhibited nanomolar activity against wild-type FLT3, FLT3-Internal tandem duplications (FLT3-ITD), and FLT3-D835Y (FLT3-TKD) mutation (IC50 = 43.8, 97.2, and 92.5 nM respectively).	benzimidazole	110-123	fms related receptor tyrosine kinase 3	Homo sapiens	204-208	
35033885-4	2022	Guided by ligand-based design and structure simplification of the FLT3 inhibitor, quizartinib, we developed a benzimidazole-based small molecule, 4ACP, that exhibited nanomolar activity against wild-type FLT3, FLT3-Internal tandem duplications (FLT3-ITD), and FLT3-D835Y (FLT3-TKD) mutation (IC50 = 43.8, 97.2, and 92.5 nM respectively).	benzimidazole	110-123	fms related receptor tyrosine kinase 3	Homo sapiens	210-214	
35033885-4	2022	Guided by ligand-based design and structure simplification of the FLT3 inhibitor, quizartinib, we developed a benzimidazole-based small molecule, 4ACP, that exhibited nanomolar activity against wild-type FLT3, FLT3-Internal tandem duplications (FLT3-ITD), and FLT3-D835Y (FLT3-TKD) mutation (IC50 = 43.8, 97.2, and 92.5 nM respectively).	benzimidazole	110-123	fms related receptor tyrosine kinase 3	Homo sapiens	245-249	
35033885-4	2022	Guided by ligand-based design and structure simplification of the FLT3 inhibitor, quizartinib, we developed a benzimidazole-based small molecule, 4ACP, that exhibited nanomolar activity against wild-type FLT3, FLT3-Internal tandem duplications (FLT3-ITD), and FLT3-D835Y (FLT3-TKD) mutation (IC50 = 43.8, 97.2, and 92.5 nM respectively).	benzimidazole	110-123	fms related receptor tyrosine kinase 3	Homo sapiens	260-264	
35033885-4	2022	Guided by ligand-based design and structure simplification of the FLT3 inhibitor, quizartinib, we developed a benzimidazole-based small molecule, 4ACP, that exhibited nanomolar activity against wild-type FLT3, FLT3-Internal tandem duplications (FLT3-ITD), and FLT3-D835Y (FLT3-TKD) mutation (IC50 = 43.8, 97.2, and 92.5 nM respectively).	benzimidazole	110-123	fms related receptor tyrosine kinase 3	Homo sapiens	272-276	
31571509-3	2019	Several benzimidazole derivatives 5a-5g and 6a-6c containing various hydrophobic moieties were synthesised, and their inhibitory activity against FLT3 was evaluated.	benzimidazole	8-21	fms related receptor tyrosine kinase 3	Homo sapiens	146-150